• Cefiderocol Activity in Resistant European Non-Fermenters

  2026-10-01

  This European surveillance study directly compared cefiderocol with newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including meropenem-resistant isolates. Cefiderocol retained high in vitro susceptibility across resistant subsets, while genomic findings implicated iron-uptake pathway changes in many cefiderocol-resistant isolates and support parallel susceptibility testing rather than assumptions based on cross-resistance.

• Idoxuridine Workflows for Viral DNA Research

  2026-09-30

  Idoxuridine provides a mechanistically grounded way to interrogate viral DNA synthesis, but reliable results depend on stock handling, matched vehicle controls, and orthogonal genome, infectivity, and cell-health readouts. This workflow also adapts a rapid, reversible perturbation strategy from human neuron research without implying that the pain study validates antiviral activity.

• Cefoperazone Sodium Salt for Resistance Assays

  2026-09-30

  Cefoperazone sodium salt supports reproducible MIC, MBC, β-lactamase stability, and biliary tract infection research workflows. This guide translates comparative antimicrobial evidence into practical assay design, formulation controls, and troubleshooting decisions for gram-negative bacterial resistance studies.

• 5-(N,N-dimethyl)-Amiloride in Endothelial Assays

  2026-09-29

  Use 5-(N,N-dimethyl)-Amiloride hydrochloride to separate Na+/H+ exchanger-dependent pH and sodium flux from downstream endothelial barrier injury. This workflow pairs DMA with moesin, permeability, and signaling readouts for more informative sepsis and cardiovascular research.

• Mouse Neutrophil Cell Isolation Kit for Tumor Assays

  2026-09-29

  Build cleaner neutrophil assays for tumor immunology, cytokine response studies, and mRNA nanovaccine validation. Negative selection removes labeled unwanted cells while leaving target neutrophils untouched, supporting high-purity, function-focused experiments.

• From CRISPR Hits to Host-State Biology in Brucella

  2026-09-28

  A translational framework for moving from host-gene discovery in Brucella infection to experimentally controlled macrophage-state perturbation with SDF-1beta (CXCL12), human recombinant.

• Nitrocefin Assays for β-Lactamase Research

  2026-09-28

  Nitrocefin turns β-lactamase activity into a rapid yellow-to-red signal, making it useful for enzyme characterization and first-pass inhibitor screening. This guide shows how to build a controlled assay, interpret results cautiously, and apply the readout to emerging resistance research such as GOB-38 in Elizabethkingia anophelis.

• Aztreonam Workflows for Gram-Negative Research

  2026-09-27

  Build reproducible Gram-negative research assays with Aztreonam, a monocyclic β-lactam antibiotic suited to studying bacterial cell-wall inhibition and resistance phenotypes. Practical guidance covers solution preparation, exploratory susceptibility workflows, assay controls, and the limits of translating preclinical findings across experimental systems.

• BML-277 and the CHK2–cGAS Genome-Integrity Axis

  2026-09-26

  Explore how BML-277, a potent Chk2 inhibitor, can help researchers test the connection between DNA damage signaling and nuclear cGAS control of LINE-1 activity. This article translates a recent mechanistic discovery into cautious, testable assay strategies while distinguishing established findings from hypotheses.

• Ceftolozane Sulfate: Assay Design for Resistance Biology

  2026-09-25

  Ceftolozane sulfate research is most informative when susceptibility results are interpreted alongside resistance mechanisms and drug exposure. This guide connects target biology, assay design, and translational models while distinguishing ceftolozane activity from that of the ceftolozane–tazobactam combination.

• Imipenem Workflows for Antibacterial Research

  2026-09-25

  Imipenem supports more than susceptibility testing: its PBP-directed antibacterial activity and reported effects on phagocytosis make it useful for paired pathogen–host assays. This workflow guide connects bench screening to emerging localized-delivery research while distinguishing established findings from exploratory applications.

• MTT Assay: Workflow, Applications & Troubleshooting

  2026-09-24

  Use MTT to compare metabolic activity across treatment groups, including bone marrow stromal cell studies, while keeping in mind that signal is not a direct cell count. This practical guide covers an adaptable workflow, controls, optimization, and the interpretation lessons from research on neohesperidin and steroid-induced osteonecrosis.

• VX-765 and the Logic of Cell-Death Assays

  2026-09-24

  VX-765 helps researchers test whether inflammatory cytokine release and macrophage pyroptosis depend on caspase-1. This article connects that focused use to new evidence that RNA polymerase II loss can trigger a distinct apoptotic response, offering a practical framework for interpreting cell-death assays without conflating mechanisms.

• Dacomitinib Workflows for Pan-HER Cancer Research

  2026-09-23

  Use Dacomitinib (PF-00299804) to interrogate ErbB signaling, durable target inhibition, and cancer-cell responses in receptor-dependent models. This workflow pairs practical dose and washout designs with a carefully bounded way to explore mitochondrial ferroptosis biology—without assuming the pathways are already linked.

• Moxidectin Boosts Polyenes Against Oral Candidiasis

  2026-09-23

  The 2024 reference study identifies moxidectin as a potentiator that increases Candida albicans ergosterol levels, thereby strengthening the activity of amphotericin B and Nystatin against fungal growth and biofilms. Transcriptomic, mutant, binding, and mouse infection experiments connect this target-amplification mechanism to reduced oral candidiasis, while also defining important limits for clinical translation.

8000 records 2/534 page Previous Next 12345 下5页 Last page